Colorado lawmakers revise effort to exempt rare disease drugs from state cost caps; European regulators find no evidence of link between new obesity medicines and suicidal thoughts

Taking stock of the drug industry, from the lab to the medicine chest

April 12, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Colorado lawmakers revise effort to exempt rare disease drugs from state cost caps An earlier bill reflected concerns patients may lose access to rare disease drugs if companies halt sales or investment in such medicines. By Ed Silverman European regulators find no evidence of link between new obesity medicines and suicidal thoughts The announcement from European regulators echoes the findings of a separate FDA review into the booming class of GLP-1 drugs. By Andrew Joseph STAT+ | The inside story of Enhertu's pan-tumor approval This week in biotechnology: Adam Feuerstein's subscriber-only newsletter digs into Enhertu and Biohaven's protein degrader. By Adam Feuerstein Listen: Vertex's big deal, biotech's red numbers, & an industry history lesson This episode, we discuss a multibillion-dollar deal from Vertex Pharmaceuticals with sweeping implications and a lengthy backstory. By Damian Garde, Allison DeAngelis, and Adam Feuerstein STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser